RESUMEN
Rheumatoid arthritis (RA) is a significant global health issue. Recent research highlights the gut microbiota's critical role in RA's development, noting how dietary factors can alter these microbial communities. This has led to an increased focus on how the gut microbiota (GM) influences RA and the potential for dietary ingredients to offer anti-RA benefits by modifying GM. This review presents a concise examination of the GM associated with RA, identifying specific microbial taxa at various levels that are implicated in the disease. It delves into dietary components known for their anti-RA properties through GM modulation and their mechanisms. Findings from numerous studies, including both animal and human research, show significant differences in the GM composition between individuals with early and established RA. Certain microbes like Tenericutes, Synergistetes, and Proteobacteria have been linked to RA progression, whereas Bacteroidetes and some strains of Lactobacillus are shown to have protective effects against RA. Dietary elements such as fibers, polysaccharides, resistant starch, and peptides have been identified as influential in combating RA. These components work by altering the GM's metabolites and impacting immune cells related to the GM. This review suggests the potential for developing functional foods aimed at treating RA by targeting GM.
RESUMEN
Traditionally, dairy products have been the primary medium for delivering probiotics to humans. However, despite their numerous health benefits, such as nutrient supply and prevention and treatment of certain diseases, there are limitations to their use in many regions, including Africa. These limitations arise from allergens, lactose intolerance, hypercholesterolemia effects, the need for vegetarian options, cultural food taboos against milk, and religious beliefs. As a result, research efforts worldwide have focused on probiotics with health benefits. To address this issue, an integrative approach has been adopted, consolidating ideas and concepts from various studies. Researchers have explored different food matrices to determine their potential as probiotic carriers, specifically emphasizing cereals and cereal products. Studies have revealed that traditional African fermented cereal-based beverages show promise as probiotic carriers due to the presence of probiotic organisms involved in the fermentation process. This presents an opportunity to utilize African cereal beverages to deliver. This review paper provides comprehensive information on probiotics, including their sources, types, health benefits, and delivery vehicles. Specifically, it highlights the challenges and prospects for developing and consuming cereal-based probiotics in Africa. This opens up new avenues for providing probiotic benefits to a broader African population and contributes to the advancement of probiotic research and development in the region.
Asunto(s)
Bebidas , Grano Comestible , Fermentación , Alimentos Fermentados , Probióticos , Humanos , Alimentos Fermentados/análisis , África , Alimentos FuncionalesRESUMEN
Bacterial pathogens have posed a serious threat to human health because they are difficult to be eliminated inside cells. Here, an effective design of poly(lactic-co-glycolic) (PLGA) nanoparticles (NPs) modified with antimicrobial peptides and loaded with gentamicin (Gen) was reported with enhanced antibacterial activity and cellular internalization ability. The results showed that the drug loading capacity and encapsulation efficiency of OVTp12-modified NPs were 7.55 % and 81.3 %, respectively. We observed that OVTp12 and OVTp12-modified NPs significantly increased the interaction with Staphylococcus aureus cells. Moreover, OVTp12-modified NPs showed an effective inhibitory effect on S. aureus with low cytotoxicity. The results of cell internalization indicated that OVTp12-modified NPs were markedly higher than that of unmodified nanoparticles when incubated with MC3T3-E1 cells. In conclusion, the bacterial cell-targeting ability of this antimicrobial peptide provides advantages for the treatment of intracellular bacterial infections.